Last updated: 2026-10-10 08:32:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Xenetic Biosciences, Inc. (XBIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.16, with a market capitalization of $4.97M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.87 to $8.87. This page covers its latest market performance, valuation, price trends and company information.
$4.97M | |
$2.12 | |
$1,074.00 | |
$1.87 | |
$2.12 | |
10.20K | |
88.89K | |
-- | |
$8.87 | |
$1.87 | |
-- | |
-- |
Xenetic Biosciences, Inc. (XBIO) last closed at $2.12 as of 2026-10-09 20:04:00, unchanged from the previous close of $2.12.
During the latest regular trading session, XBIO traded between $1.87 and $1,074.00, with a volume of 10.20K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Xenetic Biosciences, Inc. (XBIO) moved from $2.24 to $2.16, representing a decline of 3.79% ($0.09).
The stock traded between $2.10 and $2.34 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 17.18 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 4.1%
XBIO is currently trading at $2.16, placing it 4.1% of the way from its 52-week low of $1.87 to its 52-week high of $8.87. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 2 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Xenetic Biosciences, Inc. (XBIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.